ABOS: Acumen Pharmaceuticals, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
96 institutions reported holding $126.92M of Acumen Pharmaceuticals, Inc. on Form 13F (84 the quarter before). 30 opened a new position and 17 sold out. Shares held by institutions: +5%.
| Largest holders | Shares | Value |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 20,992,669 | $56.05M |
| Sands Capital Alternatives, LLC | 3,720,105 | $9.93M |
| BlackRock, Inc. | 2,490,115 | $6.65M |
| Alyeska Investment Group, L.P. | 2,454,754 | $6.55M |
| FRANKLIN RESOURCES INC | 2,305,096 | $6.15M |
| ADAR1 Capital Management, LLC | 2,111,334 | $5.64M |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,672,072 | $4.46M |
| Knollwood Investment Advisory, LLC | 1,628,510 | $4.35M |
| GEODE CAPITAL MANAGEMENT, LLC | 1,141,858 | $3.05M |
| Ikarian Capital, LLC | 1,053,797 | $2.81M |
Clinical trial readouts
1 Phase 2 or 3 trials by Acumen Pharmaceuticals, Inc. with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2026-10 (est.) | sabirnetug | Alzheimer Disease | Phase 2 | 542 | Enrollment complete | NCT06335173 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.